Form 4 Filing for MAIA Biotechnology, Inc. - Stan Smith Transaction

On December 22, 2025, Stan Smith, a director at MAIA Biotechnology, Inc. (MAIA), acquired 57,189 shares of common stock through a Securities Purchase Agreement, executed under the Issuer's 2021 Equity Incentive Plan. The shares were purchased at a price of $1.224 per share, resulting in a post-transaction ownership of 1,421,478 shares. Additionally, on the same date, Smith acquired 57,189 stock options under the same plan, exercisable beginning six months after issuance and expiring three years later. These options were acquired at a price of $1.36 per share, with an exercise price of $1.36. The filing indicates that these securities are beneficially owned through various trusts, including The Stan V. Smith Trust, and family trusts, with Smith disclaiming beneficial ownership except to the extent of his pecuniary interest.